LCMC3: Neoadjuvant atezolizumab safe, meets primary endpoint of pathologic response rate

(International Association for the Study of Lung Cancer) Primary analysis of the Lung Cancer Mutation Consortium (LCMC) 3 study revealed that neoadjuvant atezolizumab prior to lung cancer surgery was well tolerated by patients and met its primary endpoint of 20% major pathologic response rate, according to research presented today at the International Association for the Study of Lung Cancer's World Conference on Lung Cancer.